According to a recent report on BioSpace, Otsuka Pharmaceutical’s investigational therapy Voyxact is gaining momentum in IgA nephropathy (IgAN) after new Phase 3 results showed meaningful preservation of kidney function,…
As reported on Healio, glucagon-like peptide-1 (GLP-1)–based therapies are rapidly reshaping the landscape of diabetes and chronic kidney disease (CKD) management. Originally developed for glycemic control, these agents now play…
Right now, more people than ever are hoping for a kidney transplant — but the system is struggling to keep up. According to Becker’s Clinical Leadership, even a small increase…
According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), eating the right diet is essential to managing chronic kidney disease. The NIDDK recommends that patients find…
In honor of Kidney Awareness Month, we would like to congratulate the National Kidney Foundation on celebrating 75 years as an organization fighting against kidney disease and for kidney disease…
Editor's Note: Chronic conditions and rare diseases don't discriminate, Patient Worthy and its partners are interested in amplifying the voices of those from all identities and backgrounds. If you have…
Researchers from the National Institutes of Health and the Human Hereditary and Health in Africa (H3Africa) Kidney Research Network reported that people from West Africa with one genetic risk variant…
According to a recent report in Healio News, the GLP-1 agonists are medications developed primarily to control blood sugar levels for type two diabetes. About the FLOW Clinical Trial The…
In April 2024, biotechnology company Vertex Pharmaceuticals ("Vertex") shared via news release that it was advancing its therapeutic candidate inaxaplin (VX-147) into the Phase 3 portion of a Phase 2/3…
On April 30, 2024, the American Kidney Fund (AKF) will be organizing the first annual APOL1-mediated kidney disease (AMKD) Awareness Day. This awareness day will be a time to…
According to a story from drugs.com, a combination therapy for chronic kidney disease has shown considerable potential in a recent phase IIb clinical trial. The combination being evaluated consisted of…
What do clinical evaluations, blood tests, urine tests, kidney tissue tests, and imaging tests all have in common? These are all diagnostic measures that doctors may use to diagnose chronic…
Have you ever heard of dysgeusia? Dysgeusia is a condition in which someone's taste is altered, making all foods taste either bitter, sour, sweet, or metallic. Research has shown…
Anemia is a common symptom for chronic kidney disease (CKD), but there hasn't been much research done on the association between the two or the adverse outcomes which ensue as…
In 1960, the FDA approved chlorthalidone for hypertension (high blood pressure). However, doctors were unsure whether this therapy could benefit patients with advanced chronic kidney disease (CKD) who had high…
A recent clinical trial called CREDENCE has uncovered that canagliflozin, a sodium-glucose cotransporter 2 (SGLT2), can reduce hyperkalemia risk in chronic kidney disease (CKD) and type 2 diabetes patients who…
According to a recent article, a study shows patients with nondialysis-dependent chronic kidney disease and transient or chronic hyperkalemia, correspond with major adverse cardiovascular events (MACE) and even death. Chronic…
Dr. Bakris, Dr. Agarwal, Dr. Wright, and Dr. Minkoff have recently come together to discuss how they assess kidney function and ultimately diagnose chronic kidney disease (CKD). Assessing Disease Severity…
A recent study has investigated the association between cardiovascular disease risk factors and fat distribution. Researchers used linear regression analyses and adjusted for insulin sensitivity and other factors. Previous research…
A recent study investigated the experiences of patients with chronic hypoparathyroidism in pregnancy. The study ultimately found that these patients typically had low risk pregnancies and normal outcomes. However, they…
Despite drug developers' best efforts, the path to approval is not always easy. Ask biotechnology company Ardelyx, whose potential treatment option tenapanor was recently rejected by the FDA. According to…
Adetola Olajide Ariori is an artist from Ibadan, the capital of Oyo State, Nigeria. He was diagnosed with chronic kidney disease two years ago and has been living in excruciating…
According to BioSpace, Farxiga (dapagliflozin), a treatment for patients with chronic kidney disease (CKD) and a risk of progression, recently became FDA-approved. Developed by AstraZeneca, the therapy is specifically designed…
For patients with chronic kidney disease (CKD), the diagnostic journey can be long and arduous. Unfortunately, many individuals are not diagnosed until later stages of the disease. As a result,…
The National Kidney Foundation has partnered with Bayer to launch and run the "Are You the 33%?" campaign, which intends to raise awareness about the heightened risk of chronic kidney…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
